

Luigi Elio Adinolfi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1654709/publications.pdf>

Version: 2024-02-01

96
papers

5,649
citations

94433

37
h-index

79698

73
g-index

97
all docs

97
docs citations

97
times ranked

6009
citing authors

#	ARTICLE	IF	CITATIONS
1	Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. <i>Hepatology</i> , 2001, 33, 1358-1364.	7.3	922
2	Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. <i>Gastroenterology</i> , 2006, 130, 1636-1642.	1.3	517
3	Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. <i>Gastroenterology</i> , 2004, 126, 586-597.	1.3	433
4	Hepatitis B virus burden in developing countries. <i>World Journal of Gastroenterology</i> , 2015, 21, 11941.	3.3	220
5	Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. <i>World Journal of Hepatology</i> , 2013, 5, 528.	2.0	178
6	Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. <i>Atherosclerosis</i> , 2012, 221, 496-502.	0.8	164
7	Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. <i>British Journal of Haematology</i> , 2001, 113, 590-595.	2.5	161
8	Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. <i>World Journal of Gastroenterology</i> , 2014, 20, 3410.	3.3	140
9	Nonalcoholic fatty liver disease: Evolving paradigms. <i>World Journal of Gastroenterology</i> , 2017, 23, 6571-6592.	3.3	138
10	Chronic hepatitis C virus infection and neurological and psychiatric disorders: An overview. <i>World Journal of Gastroenterology</i> , 2015, 21, 2269.	3.3	134
11	Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. <i>Hepatology</i> , 2005, 41, 995-1003.	7.3	113
12	The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-8.	2.3	106
13	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018, 69, 18-24.	3.7	98
14	Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. <i>Journal of Hepatology</i> , 2008, 48, 399-406.	3.7	97
15	Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. <i>Cardiovascular Diabetology</i> , 2021, 20, 145.	6.8	91
16	Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1677-1683.	2.3	88
17	NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. <i>International Journal of Molecular Sciences</i> , 2016, 17, 803.	4.1	85
18	Chronic HCV infection is a risk factor of ischemic stroke. <i>Atherosclerosis</i> , 2013, 231, 22-26.	0.8	80

#	ARTICLE	IF	CITATIONS
19	Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. <i>Cardiovascular Diabetology</i> , 2019, 18, 24.	6.8	78
20	Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , 2020, 296, 40-47.	0.8	78
21	Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-8.	2.3	69
22	Hepatitis C and diabetes: the inevitable coincidence?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 293-308.	4.4	66
23	Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1379-1382.	2.8	64
24	Metformin: An old drug against old age and associated morbidities. <i>Diabetes Research and Clinical Practice</i> , 2020, 160, 108025.	2.8	64
25	Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. <i>Processes</i> , 2021, 9, 135.	2.8	62
26	Metabolic alterations and chronic hepatitis C: treatment strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2215-2234.	1.8	61
27	Liver fibrosis by FibroScan [®] independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. <i>Liver International</i> , 2020, 40, 347-354.	3.9	59
28	Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2408-2416.	4.4	58
29	Applicability of telemedicine in the screening of diabetic retinopathy (DR): The first multicentre study in Italy. The No Blind Study. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 35, e3113.	4.0	55
30	TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. <i>Liver International</i> , 2015, 35, 1959-1963.	3.9	51
31	Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics. <i>Cancers</i> , 2020, 12, 1351.	3.7	50
32	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. <i>Journal of Translational Medicine</i> , 2019, 17, 292.	4.4	49
33	Chronic Hepatitis C Virus Infection and Depression. <i>Clinics in Liver Disease</i> , 2017, 21, 517-534.	2.1	46
34	Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 334-340.	4.4	44
35	A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. <i>Viruses</i> , 2021, 13, 2249.	3.3	42
36	Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2345-2353.	2.6	40

#	ARTICLE	IF	CITATIONS
37	Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O ₂ Therapy: A Prospective Controlled Nonrandomized Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e403-e409.	5.8	40
38	Body composition and hepatic steatosis as precursors of fibrosis in chronic hepatitis C patients. <i>Hepatology</i> , 1999, 30, 1530-1531.	7.3	39
39	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 1458.	3.3	38
40	Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. <i>Exploration of Medicine</i> , 2020, 1, .	1.5	37
41	Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study. <i>PLoS ONE</i> , 2020, 15, e0243700.	2.5	36
42	High HDL cholesterol: A risk factor for diabetic retinopathy? Findings from NO BLIND study. <i>Diabetes Research and Clinical Practice</i> , 2019, 150, 236-244.	2.8	35
43	Seasonal variations of hyponatremia in the emergency department: Age-related changes. <i>American Journal of Emergency Medicine</i> , 2017, 35, 749-752.	1.6	33
44	Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3013-3019.	2.3	33
45	Diseases associated with electrolyte imbalance in the ED: age-related differences. <i>American Journal of Emergency Medicine</i> , 2016, 34, 1923-1926.	1.6	32
46	Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?. <i>World Journal of Gastroenterology</i> , 2018, 24, 4617-4621.	3.3	31
47	Metformin lactic acidosis: Should we still be afraid?. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107879.	2.8	30
48	The predictive value of steatosis in hepatitis C virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 205-213.	3.0	26
49	Circulating MiRNA-195-5p and -451a in Diabetic Patients with Transient and Acute Ischemic Stroke in the Emergency Department. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7615.	4.1	22
50	Sonoporation by microbubbles as gene therapy approach against liver cancer. <i>Oncotarget</i> , 2018, 9, 32182-32190.	1.8	22
51	Circulating MiRNA-195-5p and -451a in Transient and Acute Ischemic Stroke Patients in an Emergency Department. <i>Journal of Clinical Medicine</i> , 2019, 8, 130.	2.4	19
52	Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies. <i>Clinical Transplantation</i> , 2001, 15, 415-420.	1.6	18
53	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1123-1130.	2.8	18
54	Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. <i>JGH Open</i> , 2020, 4, 713-721.	1.6	18

#	ARTICLE	IF	CITATIONS
55	Endotoxemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. <i>Infection</i> , 2018, 46, 793-799.	4.7	15
56	Relevance of lung ultrasound in the diagnostic algorithm of respiratory diseases in a real-life setting: A multicentre prospective study. <i>Respirology</i> , 2020, 25, 535-542.	2.3	15
57	The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients. <i>Saudi Journal of Gastroenterology</i> , 2018, 24, 25.	1.1	15
58	Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 0106.	1.4	15
59	Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. <i>World Journal of Hepatology</i> , 2014, 6, 677.	2.0	14
60	Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. <i>Infection</i> , 2018, 46, 231-238.	4.7	13
61	The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 595-597.	4.4	13
62	Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. <i>Minerva Medica</i> , 2021, 112, 188-200.	0.9	13
63	Cannabinoid Receptor 2-63 QQ Variant Is Associated with Persistently Normal Aminotransferase Serum Levels in Chronic Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e99450.	2.5	13
64	All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. <i>World Journal of Hepatology</i> , 2015, 7, 2363.	2.0	13
65	FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 517-519.	4.4	12
66	Expert Opinion on Managing Chronic HCV Infection in Patients with Type 2 Diabetes Mellitus. <i>Antiviral Therapy</i> , 2018, 23, 11-21.	1.0	11
67	Uncommon immune-mediated extrahepatic manifestations of HCV infection. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 1089-1099.	3.0	11
68	Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1274-1282.	1.5	11
69	NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107684.	2.3	11
70	Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3005-3010.	2.3	10
71	Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 26-34.	2.0	10
72	Hepatitis B and C virus infection and risk of haematological malignancies. <i>Journal of Viral Hepatitis</i> , 2020, 27, 4-12.	2.0	9

#	ARTICLE	IF	CITATIONS
73	CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. <i>Digestive and Liver Disease</i> , 2016, 48, 1364-1369.	0.9	8
74	Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 643-656.	3.0	8
75	Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study. <i>PLoS ONE</i> , 2021, 16, e0256903.	2.5	8
76	Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19. <i>Scientific Reports</i> , 2022, 12, 5771.	3.3	7
77	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic? Standardized National Screening or One Tailored to Local Epidemiology?. <i>Biology</i> , 2022, 11, 609.	2.8	7
78	Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment. <i>Frontiers in Immunology</i> , 2022, 13, 882064.	4.8	7
79	The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study. <i>Clinical Oral Investigations</i> , 2022, 26, 5409-5417.	3.0	6
80	Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 143-146.	1.5	5
81	Early Lymphopenia and Infections in Nontraumatic Subarachnoid Hemorrhage Patients. <i>Journal of Neurosurgical Anesthesiology</i> , 2022, 34, 243-247.	1.2	5
82	Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. <i>World Journal of Hepatology</i> , 2016, 8, 949.	2.0	5
83	Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. <i>Infezioni in Medicina</i> , 2014, 22, 331-6.	1.1	5
84	Acute rhabdomyolysis in healthy woman. <i>American Journal of Emergency Medicine</i> , 2016, 34, 113.e1-113.e2.	1.6	4
85	Atypical Presentation of a Rare Parasitic Infection with <i>Fasciola hepatica</i> : A Multidisciplinary Case Report. <i>American Journal of Case Reports</i> , 2020, 21, e924704.	0.8	4
86	PNPLA3 I148M variant as a risk factor for carotid atherosclerosis in chronic hepatitis C. <i>International Journal of Cardiology</i> , 2014, 172, 291-292.	1.7	3
87	Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment. <i>Infezioni in Medicina</i> , 2015, 23, 134-9.	1.1	3
88	Circulating miRNA-195-5p and -451a in Patients with Acute Hemorrhagic Stroke in Emergency Department. <i>Life</i> , 2022, 12, 763.	2.4	3
89	Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1806-1812.	2.6	2
90	Autonomic nervous system dysfunction correlates with microvascular damage in systemic sclerosis patients. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 256-263.	1.7	2

#	ARTICLE	IF	CITATIONS
91	No effect of MTP polymorphisms on PNPLA3 in HCV-correlated steatosis. <i>Infezioni in Medicina</i> , 2018, 26, 244-248.	1.1	2
92	Clinical impact of direct-acting antiviral treatment on patients with hepatitis C virus-related oral lichen planus. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, e113.	0.4	1
93	Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study. <i>Infezioni in Medicina</i> , 2016, 24, 278-286.	1.1	1
94	AB0648...CORRELATIONS BETWEEN NEUTROPHIL/LYMPHOCYTE RATIO AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS. , 2019, , .		0
95	Viral Hepatitis C. , 2020, , 181-195.		0
96	Risk factors for carotid atherosclerosis in chronic hepatitis C: no role of the APOC3 variant. <i>Infezioni in Medicina</i> , 2015, 23, 285-7.	1.1	0